Albireo Pharma/ US01345P1066 /

3/2/2023 9:59:58 PM	Chg. -	Volume	Bid-	Ask-	High	Low
44.29USD	-	39,689 Turnover: 1.76 mill.	-Bid Size: -	-Ask Size: -	44.69	44.02

GlobeNewswire 3/29/2022 Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Sy...

GlobeNewswire 3/1/2022 Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update

GlobeNewswire 2/28/2022 Noema Pharma Appoints Michael Gutch as Chief Financial Officer

GlobeNewswire 2/22/2022 Albireo to Report Q4 and Year-End 2021 Financial Results on March 1

GlobeNewswire 2/22/2022 NICE Recommends Albireo’s Bylvay® (odevixibat) for All PFIC Types

GlobeNewswire 2/14/2022 Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare...

GlobeNewswire 1/5/2022 Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance

GlobeNewswire 1/3/2022 Liquidia Corporation Announces Chief Executive Officer Transition

GlobeNewswire 12/16/2021 Albireo Announces Positive Topline Data from Phase 1 Study of A3907

GlobeNewswire 12/13/2021 Albireo Presenting New Bylvay™ (odevixibat) Data at NASPGHAN 2021

GlobeNewswire 12/9/2021 Albireo Announces Changes to R&D Organization

GlobeNewswire 12/2/2021 Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer

GlobeNewswire 11/12/2021 Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Reveal of New Next Gen...

GlobeNewswire 11/10/2021 Albireo to Present at Upcoming Investor Conferences

GlobeNewswire 11/4/2021 Albireo Reports Q3 Financial Results and Business Update

GlobeNewswire 10/28/2021 Albireo to Report Third Quarter 2021 Financial Results on November 4

GlobeNewswire 10/15/2021 Albireo to Showcase New Data at AASLD The Liver Meeting® 2021

GlobeNewswire 10/12/2021 Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in J...

GlobeNewswire 10/5/2021 Albireo Recognizes PFIC Awareness Day 2021

GlobeNewswire 9/15/2021 Albireo Announces Bylvay® (odevixibat) Now Available in Germany

GlobeNewswire 9/8/2021 Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 9/8/2021 Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)

GlobeNewswire 9/7/2021 Albireo Sells Priority Review Voucher (PRV) for $105 Million

GlobeNewswire 9/2/2021 Albireo to Present at Upcoming Investor Conferences

GlobeNewswire 8/5/2021 Albireo Reports Q2 Financial Results and Business Update